These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38539418)

  • 1. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.
    Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
    Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
    Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Treatment With Venetoclax Plus Azacytidine Combined With Radiation Therapy and Donor Lymphocyte Infusion in a Patient With Extramedullary Relapse of Acute Myeloid Leukemia After Stem Cell Transplantation.
    Shirato S; Iyama S; Fujimi A; Takahashi S; Kobune M
    Cureus; 2024 Feb; 16(2):e53655. PubMed ID: 38449958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
    Yang TT; Song XL; Zhao YM; Ye BD; Luo Y; Xiao HW; Chen Y; Fu HR; Yu J; Liu LZ; Lai XY; Ye YS; Lan JP; Huang H; Shi JM
    Ann Hematol; 2022 Dec; 101(12):2731-2741. PubMed ID: 36318288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 8. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
    Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
    Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
    Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
    Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Sartor C; Brunetti L; Audisio E; Cignetti A; Zannoni L; Cristiano G; Nanni J; Ciruolo R; Zingarelli F; Ottaviani E; Patuelli A; Bandini L; Forte D; Sciabolacci S; Cardinali V; Papayannidis C; Cavo M; Martelli MP; Curti A
    Br J Haematol; 2023 Aug; 202(3):599-607. PubMed ID: 37226312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
    Short NJ; Ong F; Ravandi F; Nogueras-Gonzalez G; Kadia TM; Daver N; DiNardo CD; Konopleva M; Borthakur G; Oran B; Al-Atrash G; Mehta R; Jabbour EJ; Yilmaz M; Issa GC; Maiti A; Champlin RE; Kantarjian H; Shpall EJ; Popat U
    Blood Adv; 2023 Jul; 7(14):3573-3581. PubMed ID: 37104058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.
    Chen Z; Zhen S; Zhang T; Shen Y; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Chen X; Jiang E; Han M; Feng S
    Front Oncol; 2023; 13():1137175. PubMed ID: 37035180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
    Ravindran M; Mozessohn L; Cheung M; Buckstein R; Teichman J
    Blood Adv; 2024 Feb; 8(3):629-639. PubMed ID: 38029373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Short-term Effect of Venetoclax Combined with Azacitidine and "7+3" Regimen in the Treatment of Newly Diagnosed Elder Patients with Acute Myeloid Leukemia].
    Liu XX; Wen XL; Li RQ; Zhang XL; Zhang TB; Dong CX; Wang MF; Zhang JH; Yang LH; Zhang RJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):96-103. PubMed ID: 38387906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
    Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with
    Daido Y; Sugiura H; Ishikawa T; Kuroi T; Okamoto S; Nomura N; Masunari T; Sezaki N; Nannya Y; Ogawa S; Tanimoto M
    Case Rep Oncol; 2023; 16(1):999-1006. PubMed ID: 37900854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
    Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
    Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
    Pollyea DA; Winters A; McMahon C; Schwartz M; Jordan CT; Rabinovitch R; Abbott D; Smith CA; Gutman JA
    Bone Marrow Transplant; 2022 Feb; 57(2):160-166. PubMed ID: 34645926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.